The Journal of Korean Medicine (대한한의학회지)

The Society of Korean Medicine (대한한의학회)
권호 표지
DOI QR코드

DOI QR Code

Anti-thrombotic Effects of Modified Jeho-tang using a $FeCl_3$-induced Carotid Arterial Thrombosis Model

  • Bang, Jihye (KM-Based Herbal Drug Development Group, Korea Institute of Oriental Medicine) ;
  • Lee, Ki Mo (KM-Based Herbal Drug Development Group, Korea Institute of Oriental Medicine) ;
  • Kim, Bu-Yeo (KM-Based Herbal Drug Development Group, Korea Institute of Oriental Medicine) ;
  • Lee, Jeong-Hwa (Literature&Informatics Research division, Korea Institute of Oriental Medicine) ;
  • Lee, In Sun (KM-Based Herbal Drug Development Group, Korea Institute of Oriental Medicine) ;
  • Jeon, Won Kyung (KM-Based Herbal Drug Development Group, Korea Institute of Oriental Medicine)
  • Received : 2013.05.16
  • Accepted : 2013.06.05
  • Published : 2013.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives: The aim of this study was to examine the antithrombotic effects of the four herbal ingredients (Mume Fructus, MF; Santali Albi Lignum, SAL; Amomi Tsao-Ko Fructus, ATF; and Amomi Fructus, AF) of modified Jeho-tang (MJHT) in a ferric chloride ($FeCl_3$)-induced carotid arterial thrombosis model. Methods: Thirty minutes prior to a 35% $FeCl_3$ application, Sprague-Dawley (SD) rats were injected with saline, MF, SAL, ATF or AF (100 mg/kg, intraperitoneal injection), respectively. The effect of the MJHT ingredients was examined for time to occlusion (TTO) and thrombus weight (TW) in a $FeCl_3$-induced thrombosis model. Histological analysis was performed to examine the effect of the MJHT ingredients on collagen fiber damage using hematoxylin & eosin and Masson's trichrome staining. Results: Compared with vehicle treatment, MF, SAL and ATF treatment delayed TTO (vehicle, $8.11{\pm}0.60$ min; MF, $16.67{\pm}1.03$ min; SAL, $17.50{\pm}1.52$ min and ATF, $13.33{\pm}1.21$ min; P < 0.001) and inhibited thrombus formation (vehicle, $0.79{\pm}0.03$ mg/mm; MF, $0.61{\pm}0.07$ mg/mm; SAL, $0.57{\pm}0.03$ mg/mm and ATF, $0.72{\pm}0.02$ mg/mm; P < 0.001). In addition, each herbal ingredient of MJHT except for AF prevented the collagen fiber damage induced by a 35% $FeCl_3$ application. These results indicate that the MJHT ingredients MF ${\geq}$ SAL ${\geq}$ ATF ${\geq}$ AF possess antithrombotic activity in a $FeCl_3$-induced carotid arterial thrombosis. Conclusions: Altogether, these results are the first evidence that the MJHT ingredients MF, SAL and ATF have the ability to prevent vascular damage and thrombus formation in $FeCl_3$-induced carotid arterial thrombosis.

Keywords

References

  1. Owens AP, Mackman N. Tissue factor and thrombosis: The clot starts here. Thromb Haemost. 2010;104(3): 432-9. https://doi.org/10.1160/TH09-11-0771
  2. Rader DJ, Daugherty A. Translating molecular discoveries into new therapies for atherosclerosis. Nature. 2008;451(7181):904-13. https://doi.org/10.1038/nature06796
  3. Baek KM, Roh SS. Effects of Aqueous extract of diospyros Kaki Calyx on ant-thrombotic activity in vitro and in vivo. Kor J Herblology. 2011;26(4):139-47.
  4. Leadley Jr RJ, Chi L, Rebello SS, Gagnon A. Contribution of in vivo models of thrombosis to the discovery and development of novel antithrombotic agents. J Pharmacol Toxicol Methods. 2000;43(2):101-16. https://doi.org/10.1016/S1056-8719(00)00095-2
  5. Kurz KD, Main BW, Sandusky GE. Rat model of arterial thrombosis induced by ferric chloride. Thromb Res. 1990; 60(4):269-80. https://doi.org/10.1016/0049-3848(90)90106-M
  6. Konstantinides S, Schafer K, Thinnes T, Loskutoff DJ. Plasminogen activator inhibitor-1 and its cofactor vitronectin stabilize arterial thrombi after vascular injury in mice. Circulation . 2001;103(4):576-83. https://doi.org/10.1161/01.CIR.103.4.576
  7. Elg M, Gustafsson D, Carlsson S. Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat. Thromb Res. 1999; 94(3):187-97. https://doi.org/10.1016/S0049-3848(98)00213-8
  8. Schwarz M, Meade G, Stoll P, Ylanne J, Bassler N, Chen YC, et al. Conformation-specific blockade of the integrin GPIIb/IIIa: a novel antiplatelet strategy that selectively targets activated platelets. Circ Res. 2006; 99(1):25-33. https://doi.org/10.1161/01.RES.0000232317.84122.0c
  9. Iwatsuki Y, Kawasaki T, Hayashi K, Moritani Y, Nii T, Miyata K. Combined effects of a factor Xa inhibitor YM466 and a GPIIb/IIIA antagonist YM128 on thrombosis and neointima formation in mice. Thromb Haemost. 2004; 92(6):1221-8.
  10. Nishida M, Mastsuno H, Kozawa O, Ueshima S, Matsuo O, Collen D, et al. tPA, but not uPA, significantly affects antithrombotic therapy by a glycoprotein IIb/IIIa antagonist, but not by a factor Xa inhibitor. J Cardiovasc Pharmacol. 2000; 36(6):770-5. https://doi.org/10.1097/00005344-200012000-00013
  11. Hechler B, Magnenat S, Zighetti ML, Kassack MU, Ullmann H, Cazenave JP, et al. Inhibition of platelet functions and thrombosis through selective or nonselective inhibition of the platelet P2 receptors with increasing doses of NF449 [4,4',4'',4'''-(carbonylbis(imino-5,1,3-benzenetriyl bis-(carbonylimino)))tetrakis-benzene-1,3-disulf onic acid octasodium salt]. J Pharmacol Exp Ther. 2005; 314(1):232-43. https://doi.org/10.1124/jpet.105.084673
  12. Sohn HY, Kwon CS, Son KH, Kwon GS, Rye HY, Kun EJ. Antithrombin and Thrombosis Prevention Activity of Buckwheat Seed, Fagopyrum esculentum Moench. J Korea Soc Food Sci Nutr. 2006; 35(2):132-8. https://doi.org/10.3746/jkfn.2006.35.2.132
  13. Yu JY, Jin YR, Lee JJ, Chung JH, Noh JY, You SH, et al. Antiplatelet and antithrombotic activities of Korean Red Ginseng. Arch Pharm Res. 2006; 29(10):898-903. https://doi.org/10.1007/BF02973912
  14. Dubois C, Panicot-Dubois L, Merrill-Skoloff G, Furie B, Furie BC. Glycoprotein VI-dependent and -independent pathways of thrombus formation in vivo. Blood. 2006; 107(10):3902-6. https://doi.org/10.1182/blood-2005-09-3687
  15. Heo J, Donguibogam. Yoon SH, Kim HJ, editors. Korea:Donguibogam Press. 2005:1147.
  16. Min SH, Park HO, Oh HS. A study on the properties of water of Korean dried tangerine peel and development of beverage by using it. Korean J Soc Food Cookery Sci. 2002; 18(1):51-6.
  17. Ji MS, Ko BS, Ahn SW, Kim JG. A bibliographical study on Jehotang. J East Asian Soc Dietary Life. 2008; 18(1): 158-64.
  18. Ji MS, Kim JG. Analytical study on the Jehotang in Literature in terms of cooking science. J East Asian Soc Dietary Life. 2008; 18(4):446-54.
  19. Ji MS, Park MJ, Lee MY, Kim JG , Ko BS. Effect of Jehotang extract on the growth of intestinal bacteria and immunostimulation. Korean J Food Sci Technol. 2006; 38: 104-8.
  20. Jeon WK, Kim YE, Park SO, Kwon DY, Ahn SW, Lee JH, et al. The modified Jeho-tang, Korean herbal medicine, inhibits whole-blood aggregation and platelet adhesion to collagen under flow. Thromb Res. 2008; 122(6): 804-9. https://doi.org/10.1016/j.thromres.2008.03.002
  21. Kim SK, Jeon WK. Effects of Modified Jeho-tang on Ferric Chloride-induced Thrombosis in a Rat Model and of Peripheral Circulatory Disturbance in a Mouse Model. J Korean Soc Appl Biol Chem. 2010; 53(6): 842-6. https://doi.org/10.3839/jksabc.2010.128
  22. Wang X, Smith PL, Hsu MY, Ogletree ML, Schumacher WA. Murine model of ferric chloride-induced vena cava thrombosis: evidence for effect of potato carboxypeptidase inhibitor. J Thromb Haemost. 2006; 4(2): 403-10. https://doi.org/10.1111/j.1538-7836.2006.01703.x
  23. Heo EJ, Lee IS, Kang HW, Jeon WK. Effects of Sokmyong-tang on Ferric choliride-induced carotid injury thrombosis in a rat model. Korean J Oriental Physiology & Pathology. 2012; 26(5):732-7.
  24. Lee IS, Chio SG, Jeon WK. Optimization of ferric chloride induced carotid artery thrombosis model in a rat: Effect of Ginkgo biloba extracts. The Korean Journal of Clinical Laboratory Sciences. 2011; 43(4):179-87.
  25. Fuster V, Kelly BB. Promoting cardiovascular health in the developing world (A critical challenge to achieve global health). Institute of Medicine (US) Committee on Preventing the Global Epidemic of Cardiovascular Disease: Meeting the Challenges in Developing Countries. National Academies Press, Washington (DC). 2010; 275-7.
  26. Kim KS, Shin YW, Kim EI, Kim SM, Lee JE, Yoo DY. The experimental study on antithrombotic activities of Wuslsan. The Journal of Oriental Obstetrics & Gynecology. 2005;18(3):110-26.
  27. Sachs UJ, Nieswandt B. In vivo thrombus formation in murine models. Circ Res. 2007; 100(7):979-91. https://doi.org/10.1161/01.RES.0000261936.85776.5f
  28. Lee IS, Kim MY, Jeon WK. Acute toxicity study of Modified Jeho-tang in ICR mice. The Korean Journal of clinical Laboratory Sciences. 2012; 44(2):59-64.
  29. Renne T, Pozgajova M, Gruner S, Schuh K, Pauer HU, Burfeind P, et al. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med. 2005; 202(2):271-81. https://doi.org/10.1084/jem.20050664